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Abstract
Background: Neoadjuvant androgen deprivation therapy (ADT) has been suggested to confer several clinical
benefits in patients with prostate cancer (PCa) undergoing transperineal prostate brachytherapy (TPPB). Unlike
gonadotropin-releasing hormone (GnRH) receptor agonists, a GnRH antagonist such as degarelix can achieve
castrate levels of testosterone without testosterone flare. However, normalization of serum testosterone levels
following completion of neoadjuvant ADT in either form of treatment has never been compared in clinical trials.
Methods/Design: This is a single-center, open-label, randomized controlled study that will compare the efficacy
and safety of degarelix with those of existing GnRH agonists combined with 125I-TPPB. A total of 56 patients with
low/intermediate-risk clinically localized PCa will be enrolled and randomized to one of two treatment groups: the
GnRH agonist group and the degarelix group. Patients in the GnRH agonist group will receive leuprorelin acetate or
goserelin acetate, and those in the degarelix group will receive the initial dose of 240 mg as 2 subcutaneous
injections of 120 mg each, and then 80 mg of maintenance doses every 4 weeks for 12 weeks. Those randomly
assigned to the 12-week intervention period will subsequently undergo 48-weeks of follow-up after 125I-TPPB. The
primary endpoint is defined as normalization of serum testosterone levels (>50 ng/dL) following completion of
neoadjuvant ADT. All patients will be assessed every 4 weeks for the first 24 weeks, then every 12 weeks for the
next 36 weeks after administrations of these drugs. Secondary endpoints are the proportion of normalized serum
luteinizing hormone (LH) and follicle-stimulating hormone (FSH), the percent reduction in prostate specific antigen
(PSA) compared with pretreatment levels, the percent reduction in total prostate volume (TPV) during neoadjuvant
ADT, the percent increase in TPV after 125I-TPPB, the percent reduction in hemoglobin, serum alkaline phosphatase
(ALP), changes in free testosterone and bone mineral content measurement, the proportion of patients who have
serum testosterone levels over 50 ng/dL at 12 weeks following completion of neoadjuvant ADT, and the
improvement of quality of life (QOL).
Discussion: The present study will provide additional insight regarding the benefit and potency of degarelix and
will examine its potential as a new option for administration in neoadjuvant ADT.
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Background
Androgen deprivation therapy (ADT) that effectively re-
duces serum testosterone levels has been a core tool for
treating metastatic and advanced prostate cancer (PCa)
[1]. It is also an integral part of definitive treatment in
combination with radiotherapy in the management of lo-
calized and locally advanced diseases [2, 3]. In Japan,
125I-transperineal prostate brachytherapy (TPPB) has
been approved as one of the definitive options to treat
localized PCa since 2003 [4]. Efficacy of neoadjuvant and
adjuvant ADT using gonadotropin-releasing hormone
(GnRH) agonists and anti-androgen with 125I-TPPB are
currently tested in a phase III, multicenter, randomized,
controlled trial (Seed and Hormone for Intermediate-
risk Prostate Cancer (SHIP) 0804 study) [5].
Some studies have shown that patients treated with
neoadjuvant ADT have fewer positive surgical margins
but without improving biochemical control after radical
prostatectomy [6, 7]. A significant reduction in total
prostate volume (TPV) after 3 to 8-month neoadjuvant
ADT has been reported [8–12]. Although GnRH ago-
nists have been used for many years as ADT, they may
be associated with a counterintuitive initial testosterone
surge that can delay castration and which may stimulate
PCa cells, resulting in potentially detrimental exacerba-
tion of clinical symptoms particularly in advanced dis-
eases [13]. An alternative approach to ADT has emerged
in the form of a GnRH antagonist that involves the dir-
ect and rapid blockade of GnRH receptors, producing
rapid suppression of testosterone and prostate specific
antigen (PSA) levels. The effect occurs more rapidly than
with GnRH agonists, without testosterone flare. Studies
that evaluate the optimal agents and duration of ADT
that produce outcomes with fewer adverse events are
thus important.
Treatment with ADT is not avoid of adverse events,
such as fatigue, diminished sexual function hot flushes
and most importantly cardiovascular disease(CVD)
which mainly due to a suppression of testosterone
[14–16]. Many studies have shown testosterone recov-
eries after discontinuance of ADT. The extent and time
to normalization of serum testosterone are relevant to
the pre-treatment patients’ characteristics such as ages,
treatment duration, pretreatment testosterone level,
species, Gleason score and the level of dihydroxytes-
tosterone [17–21]. However, most of those studies are
retrospectively designed and inconclusive owing to the
unavailability of pretreatment testosterone. Regarding
adverse events, the results from previous studies are
controversial and confusing. Shore ND et al. stated the
potential advantages of GnRH antagonists in adverse
events and oncological outcome [22], while Kimura T
et al. questioned the real advantage of that drug [23].
In this study, we hypothesized 3 months GnRH antag-
onist to be more advantageous than GnRH agonists
owing to more rapid recovery of serum testosterone
after discontinuation. This may result in reduced inci-
dence of ADT-related adverse events.
We describe our study protocol for low/intermediate-
risk PCa, which is a single-center, open-label, random-
ized controlled study of a 12-week intervention period
as neoadjuvant ADT followed by 48-weeks follow-up
after 125I-TPPB. Japanese regulations specify the max-
imum permitted number of seeds for use, and the max-
imum intensity of radiation [5, 24]. To comply with these
requirements, it is our common practice to administer
neoadjuvant ADT even for low- to intermediate-risk PCa
in patients with relatively large prostate glands (≥40 ml).
In this study, we will evaluate temporal changes in serum
testosterone levels and TPV before and after the discon-
tinuation of short-term degarelix and GnRH agonist ad-
ministration. The final goal of this study is to establish an
appropriate strategy in neoadjuvant ADT for PCa without
testosterone surge or microsurges by using short-term
degarelix administration combined with 125I-TPPB.
Methods/Design
Aim of the study
To perform a comparative study between GnRH antag-
onist, degarelix and GnRH agonists on the recovery of
serum testosterone levels for low/intermediate risk PCa
after neoadjuvant ADT combined with 125I-TPPB. GnRH
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antagonist is hypothesized to have significantly more
rapid testosterone recovery after discontinuation.
Study design
The present study is designed as a single-center, open-
label, randomized controlled study to be performed in
patients with low/intermediate-risk PCa. The outline of
the study protocol is shown in Fig. 1. All patients are
randomized to one of two treatment groups in which pa-
tients receive 12 weeks neoadjuvant therapy with either
GnRH agonists or antagonist followed by 48 weeks of
follow-up after 125I-TPPB.
Intervention
All eligible patients will be assigned randomly to one of
two groups, the GnRH antagonist group and the GnRH
agonist group. The initial dose of degarelix is 240 mg
given as 2 subcutaneous injections of 120 mg each at
40 mg/ml in the abdomen. After the initial dose, the
maintenance dose of 80 mg is given as one subcutaneous
injection in the abdomen at 20 mg/ml, every 4 weeks.
Leuprorelin acetate is administered subcutaneously once
every 4 weeks at a dose of 3.75 mg, and goserelin acetate
is administered subcutaneously in the abdomen once
every 4 weeks at a dose of 3.6 mg.
Informed consent-ethics approval
This study was conducted in accordance with the
Helsinki Declaration of 1975, as revised in 2000. All
treatments for PCa are undertaken following written in-
formed consent. Study approval was granted by the Jikei
University Ethics Committee Institutional Review Board
(approval No. 25–366 ((7501)), date June 2, 2014).
Technique of 125I-TPPB
125I-TPPB for all patients is administered using an
ultrasound-guided technique with either the Mick
applicator or intraoperatively built custom linked seed
technique [5, 24, 25]. The implant is planned to deliver
a dose of at least 144 Gy to the clinical target volume,
which includes the prostatic gland and treatment mar-
gin [26]. Although individual technical aspects are
institution-dependent, efforts are made to assure opti-
mal quality control of the radiation dose based on our
over 1,000 cases of experience [27]. Computed tomog-
raphy images, taken at 2–5 mm intervals, are obtained
1 month after 125I-TPPB to determine the extent of
edema. Dose-volume histograms for the prostate, ur-
ethra, and rectum are computed to obtain post-
planning distribution data. V100 and D90 should be
over 95 % and 144 Gy respectively for the clinically tar-
geted volume [26, 28].
Definition of endpoints
Primary endpoints
The primary endpoint is defined as normalization of
serum testosterone (>50 ng/dL) after discontinuation of
GnRH agonists and antagonists.
Secondary endpoints
Secondary endpoints are: 1) the proportion of normal-
ized serum luteinizing hormone (LH) and follicle-
stimulating hormone (FSH), 2) the percent reduction in
PSA compared with pretreatment levels, 3) the percent
reduction in TPV during neoadjuvant ADT, 4) the per-
cent increase in TPV after 125I-TPPB, 5) the percent re-
duction in hemoglobin and serum alkaline phosphatase,
6) changes in free testosterone and bone mineral content
measurement, 7) the proportion of patients who have
serum testosterone levels over 50 ng/dL at 12 weeks
after completion of neoadjuvant ADT, 8) the improve-
ment of QOL using the international prostate symptom
score (IPSS) for lower urinary tract symptoms, 9) the
improvement of QOL using the Expanded Prostate
Fig. 1 Study design (UMIN000015519). Patients who meet the inclusion criteria are enrolled and randomized. Patients receive 12 weeks’
neoadjuvant therapy with GnRH agonists or degarelix followed by 48 weeks of follow-up after 125I-TPPB. Arrowheads show the time points
for assessments
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Cancer index Composite (EPIC), and 10) the improve-
ment of QOL using the international index of erectile




a. Be at least 20 years of age, with a definitive
histological diagnosis of PCa by needle biopsy.
b. Be adaptable to 125I-TPPB.
c. Have low/intermediate-risk localized PCa as follows:
low-risk PCa: cT1a-T2a, Gleason score 2–6 and
PSA < 10 ng/ml; intermediate-risk PCa: cT2b-T2c or
Gleason score 7 or PSA 10–20 ng/ml (excluding
Gleason score ≥ 8, PSA ≥ 20 ng/ml).
d. Have TPV 35–60 ml.
e. Agree in writing to participate in this clinical study
after receiving adequate explanation.
Eligibility criteria-exclusion criteria
Patients are ineligible if they:
a. Have previously received hormonal therapies
including GnRH agonists, GnRH antagonists,
antiandrogen agents, estrogen agents or orchiectomy
for PCa.
b. Are using 5α reductase inhibitors.
c. Have severe asthma (e.g. use inhaled corticosteroid
that is necessary for daily life), anaphylactic reaction,
severe urticaria and complication or medical history
of angioedema.
d. Are sensitive to mannitol.
e. Have multiple malignancies.
f. Have alanine aminotransferase (ALT) ≥ 100 IU/L or
total bilirubin ≥ 1.3 mg/dL.
g. Are for any other reason considered by the
investigator to be inappropriate for participation in
the present study.
Table 1 Assessment schedule
Closed circles indicate when each assessment is performed. Patients are monitored for unwanted symptoms and adverse events throughout the
study period
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Tracking and monitoring adverse events
Patients will be monitored for unwanted symptoms and
adverse events throughout the study period. Adverse
events reported spontaneously by the patient or ob-
served by physicians are similarly assessed and recorded.
They all must be reported to the principal investigator
and will be followed until they have abated or until a
stable situation has been reached.
Data collection
This study design was chosen to ensure accurate, stan-
dardized, and high-quality data collection. All patients
giving written informed consent to the study are asked
to complete a short family history and epidemiology
questionnaire. Electronic Data Capture (EDC) systems
licensed by Pharma Consulting Group are used to col-
lect clinical data in electronic format, with clinical data
being obtained from patient medical records. A follow-
up data form is completed by the investigator at week 4,
8, 12, 24, 36 and 48 after 125I-TPPB. These forms cap-
ture information regarding patient characteristics, serum
testosterone, free testosterone, LH, FSH, serum ALP,
hemoglobin, PSA, IPSS, IIEF5, EPIC, TPV, bone mineral
content and adverse events.
Statistical consideration
Sample size
This study is designed to examine the superiority of
GnRH antagonist over agonists in terms of testosterone
recovery after its discontinuation. In the previous studies
that investigated the time to normalization of testosterone
levels after discontinuation of GnRH agonist administra-
tion, 50 % of patients with clinically localized PCa showed
more than castration level testosterone (>50 ng/dL) within
4–5 months after 3-month GnRH agonist treatment
[29, 30]. By contrast, the time to normalization of tes-
tosterone levels for degarelix treatment was 1.6 [31] or
2 months [32]. The hazard ratio calculated from both of
median survival for time to normalization of testoster-
one levels was approximately 3.1. Assuming the hazard
ratio of 3.1, it was found that a sample size of 26 pa-
tients per group would be necessary using the log-rank
test with a significance level of 5 and power of 80 %. As-
suming that 5 % dropout rate, the target sample was set
at 28 patients per group (56 patients in total).
Statistical methods
Statistical analyses will be performed on an intention-to-
treat basis. Serum testosterone levels after neoadjuvant
ADT will be tested and normalization of serum testos-
terone levels above castration level (50 ng/dL) will be
defined as event. Survival curves will be estimated using
the Kaplan-Meier method. The log-rank test will be used
to test the differences between the two groups. The
hazard ratio will be estimated using the Cox propor-
tional hazard model. The longitudinal change of QOL
scores (IPSS, IIEF5 and EPIC) following 125I-TPPB will
also be compared between groups. Patients will be evalu-
ated for toxicity, graded according to the National Cancer
Institute Common Toxicity Criteria version 4.0 (https://
ctep.cancer.gov/protocolDevelopment/electronic_applica-
tions/ctc.htm#ctc_40). All tests will be two-sided, and a p-
value of 0.05 will be considered statistically significant.
Methods of recruitment and randomization
Recruiting began in 2015. Eligible patients are randomly
assigned to one of two treatment groups through the
EDC system. Randomization is done centrally using dy-
namic allocation [33] to obtain good between-group bal-
ance for factors including age category (<68/ ≥ 68) and
the TPV (<45 mL/ ≥ 45 mL) before administrations of
degarelix and GnRH agonists. The probability to be
assigned to the group of lowest imbalance is set to 0.8.
Patient enrollment and anticipated completion of
enrollment
Our current expectation is that the final patient will be
enrolled by March, 2017; the study will be clinically
completed by April, 2018 and results will be available
during the third quarter of 2018.
Discussion
Some previous studies that have investigated the impact
of ADT on intermediate- to high-risk PCa treated with
125I-TPPB suggested clinical advantages for the addition
of ADT to 125I-TPPB [34, 35]. Lee et al. [34] reported
that hormonal therapy consisting of LH-releasing hor-
mone agonist combined with an antiandrogen for
3 months before brachytherapy and continued for 2–3
months afterward significantly improved 5-year actuarial
freedom from biochemical failure, 79 % vs 54 % without
hormonal therapy. Contrary to these reports, there are
several reports showing that neoadjuvant ADT did not
improve outcome for any risk group [36], and a large
retrospective matched-pair analysis failed to show bene-
fit of neoadjuvant ADT combined with either 125I-TPPB
or 103Pd-TPPB [37]. Thus, there is still controversy re-
garding the impact of ADT on intermediate to high-risk
PCa treated with 125I-TPPB and the most effective and
safe treatment strategy remains to be established. It
should be critical for designing the study protocol to
take into consideration of the agents, the duration and
the optimal timing of ADT combined with 125I-TPPB.
Additionally, potential adverse events such as fatigue,
diminished sexual function, and hot flushes, caused by
this treatment should be taken into consideration. Al-
though the optimal duration of concomitant ADT for
intermediate-risk PCa when combined with 125I-TPPB
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remains unknown until the results from SHIP0804
study [5] are available, it may be possible to minimize
the duration of ADT and its related toxicities for pa-
tients who achieve a rapid fall in testosterone and PSA
after starting neoadjuvant ADT. Shortening this inter-
vention period will be expected to reduce costs and side
effects, and to improve QOL [38].
The agents that are mainly used as adjuvant ADT in-
clude estrogens, anti-androgen monotherapy, and com-
bined androgen blockade using an anti-androgen plus a
GnRH receptor agonist [1]. However, despite their effi-
cacy, GnRH agonists have several drawbacks associated
with their mechanism of action, including an initial tes-
tosterone surge. Compared to GnRH agonist, degarelix,
a recently approved GnRH receptor antagonist, can
achieve castration levels of testosterone much faster,
without the risks associated with testosterone flare.
Mason et al. recently conducted a comparative study for
the use of degarelix and GnRH agonist in neoadjuvant
ADT in combination with radiotherapy, and reported
that a short-period such as 12-weeks of degarelix treat-
ment achieved comparable efficacy with that of gosere-
lin plus bicalutamide as neoadjuvant ADT before
radiotherapy [39].
Note that our study protocol also focuses on the evalu-
ation of temporal change of testosterone levels and TPV
downsizing after withdrawal of degarelix, comparing it
with that of existing GnRH agonists, in neoadjuvant ADT
combined with 125I-TPPB. Although testosterone suppres-
sion is the primary outcome and it has been used as a sur-
rogate endpoint during the approval of several hormonal
treatments, only a few studies evaluated serum testoster-
one levels after the discontinuations of GnRH agonists
[29, 30] and degarelix administrations [31]. Given that the
TPV downsized with GnRH agonists, it might be expected
that serum testosterone would be restored to normal
levels immediately. However, suppression of testosterone
levels remained and continued to lower even more than a
half year after the discontinuation of GnRH agonist ad-
ministrations [19, 40]. By contrast, the normalization of
testosterone level to more than castration level after dis-
continuation of degarelix treatment was 1.6 [31] or
2 months [32]. Therefore, it is interesting to conduct a
comparative study on the efficacy and safety for degarelix
and GnRH agonists after the simultaneous discontinu-
ation of these treatments, however, no such study has re-
ported so far.
In conclusion, the present study is conducted to pro-
spectively evaluate the efficacy and safety of degarelix,
comparing it with the existing GnRH agonist, in neoad-
juvant ADT for patients with low/intermediate-risk PCa.
We expect that degarelix will prove to be an effective
and well-tolerated agent, providing a useful addition to
the hormonal armamentarium for PCa, and offering
patients with hormone-sensitive disease a valuable alter-
native treatment option in neoadjuvant ADT.
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